NASDAQ:AKTX

Akari Therapeutics Q3 2026 Earnings Results & Report

Akari Therapeutics logo
$6.87 +0.22 (+3.34%)
As of 02:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Akari Therapeutics was expected to report Q3 2026 earnings on November 12, 2026, after market closes. Analysts expected earnings of -$2.2350 per share. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available.

Earnings Announcement Details

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
7:00 AM ET

Akari Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$2.2350
Beat/Miss
N/A
One Year Ago EPS
N/A

Akari Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Akari Therapeutics Q3 2026 Earnings FAQ

Akari Therapeutics' next earnings date is estimated for Friday, December 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Akari Therapeutics on the company's earnings history page.

Akari Therapeutics Earnings Headlines

Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Akari Therapeutics Expands 2023 Equity Incentive Share Pool
See More Akari Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akari Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akari Therapeutics and other key companies, straight to your email.

About Akari Therapeutics

Akari Therapeutics (NASDAQ:AKTX) is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer. Its research includes CAR T-cell treatments intended to target solid tumors.

The company’s oncology pipeline has included AKTX-101, a mesothelin-targeting CAR T-cell candidate, and AKTX-102, which targets CD70. These candidates are investigational and have not been approved for commercial use.

Akari has also historically developed nomacopan, an investigational medicine that inhibits complement C5 and leukotriene B4 for inflammatory and autoimmune conditions. The company’s earlier work included research into potential uses for this treatment in rare diseases.

View Akari Therapeutics Profile